Suggest
#1 in Business Subscribe Email Print

You are here: Home > Health and Fitness > Quit Smoking > The New Pill To Stop Smoking - Chantix

Tags

  • prescription
  • companies
  • people
  • developing combination
  • developing combination

  • Links

  • High Fidelity Music Players
  • Success: The Slight-Edge Formula
  • Essaic Tea or Essiac Tea in Alternative Medicine
  • Suggest - The New Pill To Stop Smoking - Chantix

    The habit of smoking, as a physical and psychological addiction, can be almost impossible to defeat. There have been numerous smoking cessa
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    tion aids introduced to assist smokers in their struggles, from nicotine-based patches and gums to laser treatments and hypnotherapy.

    The m
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    st recent effort to help smokers overcome has been the new pill to stop smoking introduced by Pfizer in May of 2006. Chantix, as the pill i
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    s called, is a drug offering a new approach to using prescription drugs to fight nicotine addiction.

    Prior to the introduction of the new p
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    ll to stop smoking, the prescription drug most often given to smokers as they attempted to quit was buproprion, which originally came to mar
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    ket as the anti-depressant Wellbutrin. Research showed that Wellbutrin was inhibiting nicotine receptors in the brain from causing cravings
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    and as time passed and people smoked less because their nicotine cravings were not as strong, they eventually withdraw from nicotine. The
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    secret to Wellbutrin’s success was in its ability to limit the cravings.

    The Need For A Wellbutrin Alternative
    But Wellbutrin w
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    s really designed to be an antidepressant, and smokers who did not like the idea of taking an antidepressant when they were not clinically d
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    epressed were left out in the cold. So researchers decided to take what they had learned abut the workings of Wellbutrin on the brain’s nic
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    tine receptors, and apply the knowledge to the development of a new pill to stop smoking. The result was Chantix, also affecting the nicoti
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    ne receptors, but not in the same way as Wellbutrin.

    The new pill to stop smoking stimulates the release of small amounts of dopamine in th
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    brain, tricking the receptors into thinking nicotine has entered the bloodstream, and alleviating the symptoms of nicotine withdrawal. But
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    the new pill to stop smoking doesn’t stop there; it also blocks real nicotine from attaching to those receptors if the smoker has a moment
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    f weakness and lights up.

    Effectiveness of Chantix
    Clinical research indicates that the new pill to stop smoking was more effec
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    tive in helping people give up smoking than Wellbutrin. Because of these results, the FDA put Chantix on its short list for approval, signi
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    icantly reducing the time normally required for them to perform their own research.

    The new pill to stop smoking has helped 44% of those sm
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    okers who use it stop smoking during the first twelve–week course of treatment; but in the year since its introduction only 14% to 24% of u
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    ers have remained smoke-free. Because it is FDA-approved as a medical treatment for nicotine addiction, however, its use is normally covere
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    d by health insurance.

    If you have been unable to give up cigarettes, you have nothing to lose by giving the new pill to stop smoking a try


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.suggest.org.ua/article/262914/suggest-The-New-Pill-To-Stop-Smoking--Chantix.html">The New Pill To Stop Smoking - Chantix</a>

    BB link (for phorums):
    [url=http://www.suggest.org.ua/article/262914/suggest-The-New-Pill-To-Stop-Smoking--Chantix.html]The New Pill To Stop Smoking - Chantix[/url]

    Related Articles:

    Find Out How Auto Insurance Quotes Help Minimize Cost

    Experts Disagree on Definition of Writer's Block

    Type PDE-5 Inhibitors and NAION

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com

    Search Exchange Web Portal SpyderMap